Autopsy report · NCT01700348

Philips AirFlosser Study

“Terminated by financier due to low accrual \& high number of protocol deviations.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 257 participants enrolled.
• Results were posted on the registry 2 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Tufts University

Sponsor type

University, hospital or other

Conditions

Gingivitis

Interventions

Airflosser; Manual Floss

Participants

257

Sites

1

Countries

United States

Trials that died the same way

• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
  “Terminated due to low accrual.” (65% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (63% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (62% match in meaning)
• Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
  “Terminated due to slow accrual.” (62% match in meaning)
• Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
  “Terminated due to poor accrual” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.